Table 2.
Doses of various interventions in heart failure clinical trials
| Trial | Drug | Target Daily Dose |
Percent Reaching Target |
Mean Daily Dose |
|---|---|---|---|---|
| V-HeFT [64] | Hydralazine/Isosorbide dinitrate | 112.5/160mg | 55% | 270mg/136mg |
| CONSENSUS [65] | Enalapril | 40mg | - | 18.4mg |
| SOLVD Treatment [11] | Enalapril | 20 mg | - | 16.6mg |
| MERIT-HF [13] | Metoprolol CR/XL | 200mg | 64% | 159mg |
| COPERNICUS [66] | Carvedilol | 50mg | 80% | 45mg |
| COMET [67] | Metoprolol tartrate/ carvedilol | 100/50mg | 75%/78% | 85mg/42 mg |
| RALES [14] | Spironolactone | 25mg | - | 26mg |
| CHARM-ALTERNATIVE [68] | Candesartan | 32mg | - | 23mg |
| A-HeFT [16] | Hydralazine/Isosorbide dinitrate | 225/120 mg | 68% | 143mg/76mg |
| EMPHASIS [69] | Eplerenone | 50mg | 60.2% | 39.1 mg |